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This mechanism of achieving glucose homeostasis is distinct from that of metformin, which is a biguanide that suppresses hepatic glucose release and also induces weight loss via reduced calorie intake. 9 Given the complementary mechanisms of action of alogliptin and metformin, and the potential for incrementally improving glycaemic control without exacerbating safety events, there has been interest in the use of this FDC in patients with type 2 diabetes. Phase 3 clinical trials in Asian patients have shown that concomitant administration of alogliptin and metformin is effective and has a safety profile similar to that of the individual components. 10, 11 The current phase 3 study was designed to evaluate the efficacy and safety of alogliptin 12.5 mg plus metformin 500 mg FDC BID vs alogliptin or metformin alone in Asian patients with type 2 diabetes who are inadequately controlled with diet and exercise.
| MATERIALS AND METHODS
This was a phase 3, randomized, double-blind, placebo-controlled, multicentre study that was conducted at 59 sites in China, Malaysia, 
| RESULTS
Of 1258 screened patients, 647 were randomized to placebo (n = 163), alogliptin (n = 163), metformin (n = 162) or alogliptin + metformin FDC (n = 159) and were included in the efficacy and safety populations ( Figure S1 , File S1). Demographic and clinical characteristics for the randomized population were similar between study groups (Table S1 , File S1). Of the 647 treated patients, 511 (n = 104, placebo; n = 126, alogliptin; n = 135, metformin; n = 146, alogliptin + metformin FDC) completed the study. The most common reason for study discontinuation was lack of efficacy (n = 86 [64.2%] all groups).
| Efficacy
The LS mean change in HbA1c from baseline to end of treatment (Week 26) was −0.19% with placebo, −0.86% with alogliptin, −1.04%
with metformin and −1.53% with alogliptin + metformin BID (Table 1) . Changes were significantly greater (P < .0001) for aloglip- (Table S2 , File S1).
| Safety
The overall frequency of treatment-emergent AEs was similar for the 4 treatment groups: 48.4% for placebo, 46.3% for alogliptin, 47.2%
for metformin and 45.6% for alogliptin + metformin FDC (Table S3 , File S1). Across all treatment groups, upper respiratory tract infection was the most common AE, and the only AE with ≥5% incidence (range 4.9%-6.8%). The overall frequency of serious AEs (SAEs) ranged from 2.5% to 3.1%. Two SAEs were considered to be related to treatment: moderate gastroenteritis (1 event; placebo) that resolved in 8 days, and moderate unstable angina (1 event; alogliptin + metformin FDC) that resolved in 9 days. Overall, 19 patients (3.0%) experienced 23 hypoglycaemic events during the study, 6.2% in the metformin group, 3.8% in the alogliptin + metformin FDC group, 1.2% in the alogliptin group and 0.6% in the placebo group.
| DISCUSSION
This phase 3 study demonstrated significantly greater reductions in Overall, alogliptin + metformin FDC demonstrated a favourable safety profile. The incidence of hypoglycaemia (6.2%) was highest in the metformin-alone group, which is difficult to explain, as the incidence of hypoglycaemia in the alogliptin + metformin FDC group was lower (3.8%). The overall incidence of AEs and SAEs did not differ with alogliptin + metformin FDC vs each monotherapy. This finding is consistent with data from prior phase 3 clinical trials that tested concomitant alogliptin + metformin in Asian patients. [10] [11] [12] In addition, a meta-analysis of various DDP-4 inhibitors plus metformin as initial therapy revealed no increase in the risk of hypoglycaemia or prolonged gastrointestinal complaints relative to metformin monotherapy. 13 The efficacy and safety of alogliptin + metformin FDC demonstrated in this study is of particular importance because of potential study conduct/data collection and the writing of the manuscript. C.H.
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